From the Editor ’s desk....
The changing frequency in the listing of patients with end-stage HCV-induced liver disease for transplant, and the improvement of the typically impaired post-transplant survival seen in these patients, can be taken as early and strong indicators of direct acting antiviral (DAA) therapy ’s positive impact on HCV-associated disease burden. The study by Crespo et al. compared the composition of the liver transplant waiting list and the early post-transplant survival in the years before and after the availability of DAAs.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research
More News: Gastroenterology | Liver | Liver Disease | Liver Transplant | Study | Transplant Surgery | Transplants | Urology & Nephrology